entecavir and Polycythemia-Vera

entecavir has been researched along with Polycythemia-Vera* in 2 studies

Other Studies

2 other study(ies) available for entecavir and Polycythemia-Vera

Article	Year
Occult hepatitis B infection reactivation after ruxolitinib therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:6 Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; Hydroxyurea; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tenofovir; Virus Activation	2017
Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:10 Ruxolitinib is a useful treatment option for myelofibrosis since it effectively resolves splenomegaly and constitutional symptoms. After the widespread use of ruxolitinib outside of clinical trials, a series of case reports indicated a potential risk of ruxolitinib-associated opportunistic infections, including the reactivation of the hepatitis B virus (HBV). We herein report the case of a polycythemia vera patient who showed an elevation of HBV-DNA viral DNA with an elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) after the initiation of ruxolitinib. Anti-viral therapy with entecavir was immediately started and the HBV viral load thereafter decreased with an improvement of the liver function. Physicians should thus be aware of the potential risk of ruxolitinib-associated HBV reactivation. Topics: Alanine Transaminase; Aspartate Aminotransferases; DNA, Viral; Female; Guanine; Hepatitis B virus; Humans; Janus Kinases; Middle Aged; Nitriles; Polycythemia Vera; Pyrazoles; Pyrimidines; Splenomegaly	2016

Article

Year

Occult hepatitis B infection reactivation after ruxolitinib therapy.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:6

Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; Hydroxyurea; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tenofovir; Virus Activation

2017

Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.

Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:10

Ruxolitinib is a useful treatment option for myelofibrosis since it effectively resolves splenomegaly and constitutional symptoms. After the widespread use of ruxolitinib outside of clinical trials, a series of case reports indicated a potential risk of ruxolitinib-associated opportunistic infections, including the reactivation of the hepatitis B virus (HBV). We herein report the case of a polycythemia vera patient who showed an elevation of HBV-DNA viral DNA with an elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) after the initiation of ruxolitinib. Anti-viral therapy with entecavir was immediately started and the HBV viral load thereafter decreased with an improvement of the liver function. Physicians should thus be aware of the potential risk of ruxolitinib-associated HBV reactivation.

Topics: Alanine Transaminase; Aspartate Aminotransferases; DNA, Viral; Female; Guanine; Hepatitis B virus; Humans; Janus Kinases; Middle Aged; Nitriles; Polycythemia Vera; Pyrazoles; Pyrimidines; Splenomegaly

2016